Myriad Genetics, Inc. has announced new clinical data from the MONSTAR-SCREEN 3 study, conducted in collaboration with the National Cancer Center Hospital East in Japan. The study demonstrated the effectiveness of Myriad's Precise™ MRD Test in detecting and monitoring circulating tumor DNA (ctDNA) across multiple cancer types. The results, presented at the 2025 ASCO Annual Meeting, showed 100% detection of ctDNA at baseline and indicated that 60% of patients tested positive for ctDNA one month after surgery, with tumor fractions detectable only through the ultra-sensitive test. The Precise MRD Test, informed by whole-genome sequencing, tracks numerous tumor-specific sites, enhancing sensitivity even in cancers with low shedding tumors. Findings suggest that ctDNA clearance during neoadjuvant chemotherapy predicts a pathological complete response, and patients with ultra-sensitive ctDNA positive results post-surgery had worse disease-free survival.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.